Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated wit ...

Danone has launched a drinkable yogurt product under its Oikos brand in the US which looks to target users of Ozempic and ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

A company that has Donald Trump Jr. on its board debuted a new service to help pharmaceutical companies launch direct sales ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...